DK1478373T3 - Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12 - Google Patents

Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12

Info

Publication number
DK1478373T3
DK1478373T3 DK02780174T DK02780174T DK1478373T3 DK 1478373 T3 DK1478373 T3 DK 1478373T3 DK 02780174 T DK02780174 T DK 02780174T DK 02780174 T DK02780174 T DK 02780174T DK 1478373 T3 DK1478373 T3 DK 1478373T3
Authority
DK
Denmark
Prior art keywords
tetrahydrofolic acid
tetrahydrofolic
vitamin
dosage units
tetrahydrofolate
Prior art date
Application number
DK02780174T
Other languages
Danish (da)
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1478373T3 publication Critical patent/DK1478373T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK02780174T 2002-02-21 2002-11-15 Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12 DK1478373T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02075695 2002-02-21

Publications (1)

Publication Number Publication Date
DK1478373T3 true DK1478373T3 (da) 2007-01-15

Family

ID=27741182

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02780174T DK1478373T3 (da) 2002-02-21 2002-11-15 Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12

Country Status (29)

Country Link
US (1) US20050164977A1 (no)
EP (1) EP1478373B1 (no)
JP (1) JP5037779B2 (no)
KR (1) KR100936827B1 (no)
CN (1) CN1620302B (no)
AT (1) ATE341333T1 (no)
AU (1) AU2002343249B2 (no)
BR (1) BR0215613A (no)
CA (1) CA2476940C (no)
CR (1) CR7420A (no)
CY (1) CY1106273T1 (no)
DE (1) DE60215224T2 (no)
DK (1) DK1478373T3 (no)
EA (1) EA007599B1 (no)
EC (1) ECSP045305A (no)
ES (1) ES2274107T3 (no)
HK (1) HK1078780A1 (no)
HU (1) HUP0402674A3 (no)
IL (2) IL163579A0 (no)
ME (1) MEP37208A (no)
MX (1) MXPA04008185A (no)
NO (1) NO20043932L (no)
NZ (1) NZ534806A (no)
PL (1) PL209558B1 (no)
PT (1) PT1478373E (no)
RS (1) RS50909B (no)
UA (1) UA80965C2 (no)
WO (1) WO2003070255A1 (no)
ZA (1) ZA200407545B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
AU2013202756B2 (en) * 2006-07-06 2015-06-04 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
BRPI0713999A2 (pt) * 2006-07-06 2012-11-20 Bayer Schering Pharma Ag produÇço farmacÊutica para contracepÇço e para reduÇço do risco de malformaÇÕes congÊnitas
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
GB0715502D0 (en) * 2007-08-08 2007-09-19 Univ Manchester Methods
CN101945646A (zh) * 2008-02-13 2011-01-12 拜耳先灵医药股份有限公司 含雌二醇的药物递送系统
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2324832B2 (de) * 2009-11-09 2016-11-30 Biogena Naturprodukte GmbH & Co KG Nahrungsergänzungsmittel bei Einnahme von hormonellen Kontrazeptiva
KR101994805B1 (ko) 2011-06-01 2019-07-01 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ES2925534T3 (es) * 2011-11-05 2022-10-18 South Alabama Medical Science Found Métodos, formulaciones y kits para reponer rápidamente los niveles de folato en mujeres
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2932855C (en) * 2013-12-12 2022-07-19 Donesta Bioscience B.V. Orally disintegrating solid dosage unit containing an estetrol component
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CN116077455A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0877563T3 (da) * 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
EP0934060A4 (en) * 1996-07-30 2001-01-03 Energetics FOOD SUPPLEMENTS
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US6220453B1 (en) * 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
EP1071428A2 (en) * 1998-04-17 2001-01-31 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
AU4573899A (en) * 1998-06-19 2000-01-05 Beth Israel Deaconess Medical Center Dietary supplement for post-menopausal women
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) * 2000-10-24 2002-04-30 Иван ХРИСТОВ Medicamentous preparation for multiple sclerosis treatment

Also Published As

Publication number Publication date
CA2476940C (en) 2011-11-01
JP5037779B2 (ja) 2012-10-03
MEP37208A (en) 2011-02-10
HUP0402674A3 (en) 2012-12-28
BR0215613A (pt) 2004-12-07
NZ534806A (en) 2006-05-26
RS73304A (en) 2007-02-05
ECSP045305A (es) 2004-10-26
MXPA04008185A (es) 2004-11-26
AU2002343249B2 (en) 2009-02-05
ATE341333T1 (de) 2006-10-15
EP1478373B1 (en) 2006-10-04
PT1478373E (pt) 2007-01-31
CA2476940A1 (en) 2003-08-28
KR20040094711A (ko) 2004-11-10
IL163579A0 (en) 2005-12-18
ES2274107T3 (es) 2007-05-16
PL209558B1 (pl) 2011-09-30
ZA200407545B (en) 2006-06-28
DE60215224D1 (de) 2006-11-16
EP1478373A1 (en) 2004-11-24
CN1620302B (zh) 2011-04-27
JP2005523283A (ja) 2005-08-04
PL371441A1 (en) 2005-06-13
CN1620302A (zh) 2005-05-25
CY1106273T1 (el) 2011-10-12
US20050164977A1 (en) 2005-07-28
NO20043932L (no) 2004-11-19
DE60215224T2 (de) 2007-08-23
KR100936827B1 (ko) 2010-01-14
AU2002343249A1 (en) 2003-09-09
HK1078780A1 (en) 2006-03-24
WO2003070255A1 (en) 2003-08-28
IL163579A (en) 2011-03-31
HUP0402674A2 (hu) 2005-04-28
EA007599B1 (ru) 2006-12-29
CR7420A (es) 2006-02-06
RS50909B (sr) 2010-08-31
UA80965C2 (en) 2007-11-26
EA200401014A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
DK1478373T3 (da) Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12
CN101489563A (zh) 用于避孕和预防先天性畸形风险的药物制剂
US6011040A (en) Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
WO1999053910A2 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
WO2006099233B1 (en) Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
KR20090029824A (ko) 피임용 및 선천성 기형 위험 예방용 제약 제제
CA2696030A1 (en) Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for therapy of endometriosis with simultaneous reduction of therapy side effects and reduction of the risk of congenital abnormalities at the onset of a pregnancy
PT1148882E (pt) Utilização de um agente redutor do teor de homocisteína no plasma para redução do risco de efeitos secundários tromboembólicos induzidos por hormonas do tipo dos gestagénios
EP1891959A1 (de) Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen